Cost-effectiveness of the regimen proposed by the International Consortium on Acute Promyelocytic Leukemia for the treatment of newly diagnosed patients with Acute Promyelocytic Leukemia

Rodríguez-Rodríguez, Sergio; Guerrero-Torres, Lorena; Díaz-Huízar, María José; Pomerantz, Alan; Ortíz-Vilchis, María del Pilar; Demichelis-Gómez, Roberta.
Hematol., Transfus. Cell Ther. (Impr.) ; 43(4): 476-481, Oct.-Dec. 2021. tab, ilus
Artículo en Inglés | LILACS | ID: biblio-1350816

Documentos relacionados

  1. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.
  2. Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed.
  3. A Life-Threatening Complication During the Fourth Pregnancy Due to Acute Promyelocytic Leukemia: A Case Report.
  4. Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
  5. The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.
  6. Inhibition of splicing factors SF3A3 and SRSF5 contributes to As<sup>3+</sup>/Se<sup>4+</sup> combination-mediated proliferation suppression and apoptosis induction in acute promyelocytic leukemia cells.
  7. Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia.
  8. [JMJD3 Exerts Oncorepressor Activity in Acute Promyelocytic Leukemia by Promoting PU.1 Expression].
  9. Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
  10. Diagnosis of Acute Promyelocytic Leukemia After Presentation to Neuro-Ophthalmology.